Literature DB >> 12884911

FAK regulates biological processes important for the pathogenesis of cancer.

Veronica Gabarra-Niecko1, Michael D Schaller, Jill M Dunty.   

Abstract

Since its initial discovery as a substrate and binding partner for the Src oncogene, a role for the focal adhesion kinase (FAK) in cancer has been speculated. In this review the clinical evidence correlating FAK overexpression with cancer and the experimental evidence demonstrating that FAK can control some phenotypes associated with cancer will be discussed. In addition, the emerging theme of interactions between the FAK and growth factor signaling pathways will be described. The evidence presented in this review provides a compelling case for a role for FAK in the pathology of human cancer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12884911     DOI： 10.1023/a:1023725029589

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN： 0167-7659            Impact factor:   9.264


  123 in total

1.  Dieckol from Ecklonia cava suppresses the migration and invasion of HT1080 cells by inhibiting the focal adhesion kinase pathway downstream of Rac1-ROS signaling.

Authors:  Sun Joo Park; You Jin Jeon
Journal:  Mol Cells       Date:  2012-02       Impact factor: 5.034

2.  Focal adhesion kinase mediates TGF-beta1-induced renal tubular epithelial-to-mesenchymal transition in vitro.

Authors:  Bingqing Deng; Xiao Yang; Jianshe Liu; Fangfang He; Zhonghua Zhu; Chun Zhang
Journal:  Mol Cell Biochem       Date:  2010-02-23       Impact factor: 3.396

Review 3.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

4.  Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis.

Authors:  Masuo Hanada; Kazuhiro Tanaka; Yoshihiro Matsumoto; Fumihiko Nakatani; Riku Sakimura; Tomoya Matsunobu; Xu Li; Takamitsu Okada; Tomoyuki Nakamura; Minoru Takasaki; Yukihide Iwamoto
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  TGFβ, Fibronectin and Integrin α5β1 Promote Invasion in Basal Cell Carcinoma.

Authors:  François Kuonen; Isabelle Surbeck; Kavita Y Sarin; Monique Dontenwill; Curzio Rüegg; Michel Gilliet; Anthony E Oro; Olivier Gaide
Journal:  J Invest Dermatol       Date:  2018-07-14       Impact factor: 8.551

6.  Focal adhesion kinase modulates cell adhesion strengthening via integrin activation.

Authors:  Kristin E Michael; David W Dumbauld; Kellie L Burns; Steven K Hanks; Andrés J García
Journal:  Mol Biol Cell       Date:  2009-03-18       Impact factor: 4.138

7.  PTK2 rs7460 and rs7843014 polymorphisms and exceptional longevity: a functional replication study.

Authors:  Nuria Garatachea; Noriyuki Fuku; Zi-Hong He; Ye Tian; Yasumichi Arai; Yukiko Abe; Haruka Murakami; Motohiko Miyachi; Thomas Yvert; Letizia Venturini; Catalina Santiago; Alejandro Santos-Lozano; Gabriel Rodríguez; Giovanni Ricevuti; Helios Pareja-Galeano; Fabian Sanchis-Gomar; Enzo Emanuele; Nobuyoshi Hirose; Alejandro Lucia
Journal:  Rejuvenation Res       Date:  2014-10       Impact factor: 4.663

8.  FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mrozcek-Musulman; Elizabeth A Beierle
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

9.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

10.  Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.

Authors:  Constantinos T Giaginis; Stephanie Vgenopoulou; Gerasimos S Tsourouflis; Ekaterini N Politi; Gregorios P Kouraklis; Stamatios E Theocharis
Journal:  Pathol Oncol Res       Date:  2008-11-06       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.